NASDAQ:NEUP Neuphoria Therapeutics (NEUP) Stock Price, News & Analysis $4.96 -0.13 (-2.63%) As of 03:03 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Neuphoria Therapeutics Stock (NASDAQ:NEUP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Neuphoria Therapeutics alerts:Sign Up Key Stats Today's Range$4.67▼$5.1050-Day Range$3.94▼$5.3952-Week Range$3.64▼$21.40Volume62,077 shsAverage Volume44,782 shsMarket Capitalization$26.71 millionP/E RatioN/ADividend YieldN/APrice Target$21.00Consensus RatingHold Company Overview Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA. Read More Neuphoria Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreNEUP MarketRank™: Neuphoria Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 565th out of 865 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingNeuphoria Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialNeuphoria Therapeutics has a consensus price target of $21.00, representing about 340.3% upside from its current price of $4.77.Amount of Analyst CoverageNeuphoria Therapeutics has received no research coverage in the past 90 days.Read more about Neuphoria Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Neuphoria Therapeutics are expected to grow in the coming year, from ($4.07) to ($2.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neuphoria Therapeutics is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neuphoria Therapeutics is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeuphoria Therapeutics has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Neuphoria Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.87% of the float of Neuphoria Therapeutics has been sold short.Short Interest Ratio / Days to CoverNeuphoria Therapeutics has a short interest ratio ("days to cover") of 1.46, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neuphoria Therapeutics has recently increased by 97.37%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeuphoria Therapeutics does not currently pay a dividend.Dividend GrowthNeuphoria Therapeutics does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.48 News SentimentNeuphoria Therapeutics has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Neuphoria Therapeutics this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Neuphoria Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Neuphoria Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders1.50% of the stock of Neuphoria Therapeutics is held by insiders.Percentage Held by Institutions15.90% of the stock of Neuphoria Therapeutics is held by institutions.Read more about Neuphoria Therapeutics' insider trading history. Receive NEUP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neuphoria Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NEUP Stock News HeadlinesNeuphoria Therapeutics (NEUP) price target increased by 38.22% to 13.77May 14 at 9:08 AM | msn.comNeuphoria Therapeutics (NASDAQ:NEUP) Stock Price Up 1.3% - Should You Buy?May 5, 2026 | americanbankingnews.comElon Musk’s $1 Quadrillion AI IPO$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is the scale of what analysts are calling the biggest AI IPO in history.And right now, you can claim a stake before the company goes public, starting with just $500.Elon Musk is predicting this investment could climb 1,000x from here. Early access is available today.May 15 at 1:00 AM | Brownstone Research (Ad)Here's Why We're Not At All Concerned With Neuphoria Therapeutics' (NASDAQ:NEUP) Cash Burn SituationFebruary 19, 2026 | uk.finance.yahoo.comNeuphoria Therapeutics (NEUP) price target decreased by 32.33% to 9.96December 22, 2025 | msn.comLeading Advisory Firms Recommend Voting FOR Lynx1's Independent NomineesDecember 8, 2025 | marketwatch.comLeading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director NomineesDecember 8, 2025 | markets.businessinsider.comLeading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director NomineesDecember 8, 2025 | globenewswire.comSee More Headlines NEUP Stock Analysis - Frequently Asked Questions How have NEUP shares performed this year? Neuphoria Therapeutics' stock was trading at $3.88 at the beginning of 2026. Since then, NEUP stock has increased by 22.9% and is now trading at $4.77. How were Neuphoria Therapeutics' earnings last quarter? Neuphoria Therapeutics Inc. (NASDAQ:NEUP) released its quarterly earnings results on Friday, May, 15th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.47. Who are Neuphoria Therapeutics' major shareholders? Top institutional investors of Neuphoria Therapeutics include AdvisorShares Investments LLC (2.88%). View institutional ownership trends. How do I buy shares of Neuphoria Therapeutics? Shares of NEUP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today5/15/2026Last Earnings5/15/2026Next Earnings (Estimated)5/15/2026Fiscal Year End6/30/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (6m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 NEUP's financial health is in the Yellow zone, according to TradeSmith. NEUP has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NEUP Previous SymbolNASDAQ:NEUP CIK1191070 Webwww.bionomics.com.au Phone61-8-8150-7400FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Neuphoria Therapeutics$21.00 High Price Target$35.00 Low Price Target$7.00 Potential Upside/Downside+327.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($4.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$370 thousand Net MarginsN/A Pretax Margin-40.58% Return on Equity-25.98% Return on Assets-18.39% Debt Debt-to-Equity RatioN/A Current Ratio9.04 Quick Ratio9.04 Sales & Book Value Annual Sales$15.65 million Price / Sales1.69 Cash Flow$0.15 per share Price / Cash Flow31.95 Book Value$10.11 per share Price / Book0.49Miscellaneous Outstanding Shares5,390,000Free Float5,310,000Market Cap$26.48 million OptionableN/A Beta0.72 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:NEUP) was last updated on 5/15/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)A little-known stock pick with money-doubling potential over the next year is revealed for free in the first t...Paradigm Press | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuphoria Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuphoria Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
